Optimization of particle size and encapsulation efficiency of vancomycin nanoparticles by response surface methodology

References

• Huh AJ, Kwon YJ. “Nanoantibiotics”: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J Control Release 2011;156:128–145
   PubMed Web of Science ®Google Scholar
• Chakraborty SP, Mahapatra SK, Sahu SK, et al. Internalization of Staphylococcus aureus in lymphocytes induces oxidative stress and DNA fragmentation: possible ameliorative role of nanoconjugated vancomycin. Oxid Med Cell Longev 2011. doi: 10.1155/2011/942123
   Google Scholar
• Chakraborty SP, Sahu SK, Mahapatra SK, et al. Nanoconjugated vancomycin: new opportunities for the development of anti-VRSA agents. Nanotechnology 2010;21:1–9
   Google Scholar
• Chakraborty SP, Mahapatra SK, Sahu SK, et al. Nitric oxide mediated Staphylococcus aureus pathogenesis and protective role of nanoconjugated vancomycin. Asian Pac J Trop Biomed 2011;1:102–109
   PubMedGoogle Scholar
• Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138–2144
   PubMed Web of Science ®Google Scholar
• Jeffres MN, Isakow W, Doherty JA, et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007;29:1107–1115
   PubMed Web of Science ®Google Scholar
• Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agent Chemother 2008;52:1330–1336
   PubMed Web of Science ®Google Scholar
• Sivagnanam S, Deleu D. Red man syndrome. Crit Care 2003;7:119–120
   PubMed Web of Science ®Google Scholar
• Zhang L, Pornpattananangkul D, Hu CM, Huang CM. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem 2010;17:585–594
   PubMed Web of Science ®Google Scholar
• Zhang L, Gu FX, Chan JM, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008;83:761–769
   PubMed Web of Science ®Google Scholar
• Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009;86:215–223
   PubMed Web of Science ®Google Scholar
• Patel JK, PJivani N. Chitosan based nanoparticles in drug delivery. Int J Pharmaceut Sci Nanotech 2009;2:517–522
   Google Scholar
• Sailaja AK, Amareshwar P, Chakravarty P. Chitosan nanoparticles as a drug delivery system. Res J Pharm Biol Chem Sci 2010;1:474–484
   Google Scholar
• Patel MP, Patel RR, Patel JK. Chitosan mediated targeted drug delivery system: a review. J Pharm Pharmaceut Sci 2010;13:536–557
   PubMed Web of Science ®Google Scholar
• Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release 2004;100:5–28
   PubMed Web of Science ®Google Scholar
• Wang JJ, Zeng ZW, Xiao RZ, et al. Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomed 2011;6:765–774
   PubMed Web of Science ®Google Scholar
• Kavitha K, Keerthi TS, Mani TT. Chitosan polymer used as carrier in various pharmaceutical formulations: brief review. Int J Appl Biol Pharmaceut Tech 2011;2:249–258
   Google Scholar
• Li P, Wang Y, Peng Z, et al. Development of chitosan nanoparticles as drug delivery systems for 5-fluorouracil and leucovorin blends. Carbohyd Polym 2011;85:698–704
   Web of Science ®Google Scholar
• Turan K, Nagata K. Chitosan-DNA nanoparticles: the effect of cell type and hydrolysis of chitosan on in vitro DNA transfection. Pharm Dev Technol 2006;11:503–512
   PubMed Web of Science ®Google Scholar
• Luangtana-anan M, Opanasopit P, Ngawhirunpat T, et al. Effect of chitosan salts and molecular weight on a nanoparticulate carrier for therapeutic protein. Pharm Dev Technol 2005;10:189–196
   PubMed Web of Science ®Google Scholar
• Rabea EI, Badawy ME, Stevens CV, et al. Chitosan as antimicrobial agent: applications and mode of action. Biomacromolecules 2003;4:1457–1465
   PubMed Web of Science ®Google Scholar
• Chung YC, Wang HL, Chen YM, Li SL. Effect of abiotic factors on the antibacterial activity of chitosan against waterborne pathogens. Bioresour Technol 2003;88:179–184
   PubMed Web of Science ®Google Scholar
• Qi L, Xu Z, Jiang X, et al. Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr Res 2004;339:2693–2700
   PubMed Web of Science ®Google Scholar
• Don TM, Chen CC, Lee CK, et al. Preparation and antibacterial test of chitosan/PAA/PEGDA bi-layer composite membranes. J Biomat Sci Polym 2005;16:1503–1519
   PubMed Web of Science ®Google Scholar
• Loveymi BD, Jelvehgari M, Zakeri-Milani P, Valizadeh H. Design of vancomycin RS-100 nanoparticles in order to increase the intestinal permeability. Adv Pharm Bull 2012;2:43–56
   PubMedGoogle Scholar
• Loveymi BD, Jelvehgari M, Zakeri-Milani P, Valizadeh H. Statistical optimization of oral vancomycin-eudragit RS nanoparticles using response surface methodology. Iran J Pharm Res 2012;11:1001–1012
   PubMedGoogle Scholar
• Loveymi BD, Jelvehgari M, Zakeri-Milani P, Valizadeh H. The characteristics and improved intestinal permeability of vancomycin PLGA-nanoparticles as colloidal drug delivery system. Colloids Surf B Biointerfaces 2013;103:174–181
   PubMedGoogle Scholar
• Chuah LH, Billa N, Roberts CJ, et al. Curcumin-containing chitosan nanoparticles as a potential mucoadhesive delivery system to the colon. Pharm Dev Technol 2013;18:591–599
   PubMed Web of Science ®Google Scholar
• Modaresi SMS, Ejtemaei Mehr S, Faramarzi MA, et al. Preparation and characterization of self-assembled chitosan nanoparticles for the sustained delivery of streptokinase: an in vivo study. Pharm Dev Technol 2013; Early Online: 1–5. DOI: 10.3109/10837450.2013.813542
   PubMedGoogle Scholar
• Eriksson L, Johansson E, Kettaneh-wold N, et al. Design of experiments: principles and applications. Umea: Umetrics academy; 2008:8–24
   Google Scholar
• Czitrom V. One-factor-at-a-time versus designed experiments. Am stat 1999;53:126–131
   Web of Science ®Google Scholar
• Anderson-cook CM, Borror CM, Montgomery DC. Response surface design evaluation and comparison. J Stat Plan Infer 2009;139:629–641
   Web of Science ®Google Scholar
• Box GEP, Draper NR. Empirical model building and response surfaces. New York: John Wiley and Sons; 1987:477
   Google Scholar
• Box GEP, Behnken DW. Some new three level designs for the study of quantitative variables. Technometrics 1960;2:455–475
   Google Scholar
• Linkov I, Satterstrom FK, Kiker G, et al. From comparative risk assessment to multi-criteria decision analysis and adaptive management: recent developments and applications. Environ Int 2006;32:1072–1093
   PubMed Web of Science ®Google Scholar
• Calvo P, Remuñán-Lopez C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 1997;63:125–132
   Web of Science ®Google Scholar
• Yetilmezsoya K, Demirel S, Vanderbei RJ. Response surface modeling of pb(ii) removal from aqueous solution by pistacia vera l.: Box–Behnken experimental design. J Hazard Mater 2009;171:551–562
   PubMed Web of Science ®Google Scholar
• Adinarayana K, Ellaiah P. Response surface optimization of the critical medium components for the production of alkaline protease by a newly isolated Bacillus sp. J Pharm Pharm Sci 2002;5:272–278
   PubMed Web of Science ®Google Scholar